EcoDrugPlus

Tumor Protein P53

Ensembl ID : ENSSLDG00000010510
Gene Symbol: TP53
3 Cross references
232 Possible Orthologues:

Type-2 Angiotensin Ii Receptor-Like

Ensembl ID : ENSSLDG00000024181
Gene Symbol: LOC111646454
3 Cross references
185 Possible Orthologues:

Tyrosinase

Ensembl ID : ENSSLDG00000021033
Gene Symbol: TYR
3 Cross references
202 Possible Orthologues:

Tyrosinase

Ensembl ID : ENSSLDG00000022181
Gene Symbol: TYR
4 Cross references
198 Possible Orthologues:

Tyrosine Hydroxylase

Ensembl ID : ENSSLDG00000011976
Gene Symbol: TH
3 Cross references
187 Possible Orthologues:

Tyrosine Kinase 2

Ensembl ID : ENSSLDG00000014535
Gene Symbol: TYK2
3 Cross references
195 Possible Orthologues:

Tyrosine Kinase With Immunoglobulin Like And Egf Like Domains 1

Ensembl ID : ENSSLDG00000001435
Gene Symbol: TIE1
3 Cross references
205 Possible Orthologues:

Tyrosine-Protein Kinase Jak2-Like

Ensembl ID : ENSSLDG00000016144
Gene Symbol: LOC111651535
3 Cross references
199 Possible Orthologues:

Tyrosine-Protein Kinase Lyn-Like

Ensembl ID : ENSSLDG00000021626
Gene Symbol: LOC111653435
3 Cross references
195 Possible Orthologues:

Tyrosine-Protein Kinase Fyna

Ensembl ID : ENSSLDG00000019001
Gene Symbol: LOC111651009
3 Cross references
191 Possible Orthologues:

Tyrosine-Protein Kinase Yes

Ensembl ID : ENSSLDG00000009093
Gene Symbol: LOC111653171
3 Cross references
206 Possible Orthologues:

Uncharacterized Loc111646335

Ensembl ID : ENSSLDG00000020457
Gene Symbol: LOC111646335
2 Cross references
196 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).